[GDF-15 and the risk of bleeding in patients with stable CAD receiving multicomponent antithrombotic therapy: the results of the prospective REGATA register].

E N Krivosheeva A L Komarov E P Panchenko M B Khakimova E S Kropacheva Olga A Pogorelova Tatyana V Balakhonova E V Titaeva A B Dobrovolsky D M Galyautdinov E E Vlasova

Published in: Terapevticheskii arkhiv (2024)

Assessment of GDF-15 level may improve bleeding risk stratification in CAD patients with concomitant AF and/or PAD receiving combined antithrombotic therapy.

Keyphrases

atrial fibrillation
coronary artery disease
stem cells
cell therapy